Clinical trial
A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa
NCT04908215 is registered in ClinicalTrials.gov with InMed Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa
- Lead sponsor
- InMed Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 28, 2021
- Completion date
- April 19, 2023
- Enrollment
- 19 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.